REVIEW article

Front. Cell Dev. Biol., 06 January 2023

Sec. Cancer Cell Biology

Volume 10 - 2022 | https://doi.org/10.3389/fcell.2022.1077756

Synovial sarcoma of the head and neck: A review of reported cases on the clinical characteristics and treatment methods

  • 1. Department of Oral Maxillofacial Surgery, Xiangya Stomatological Hospital and School of Stomatology, Central South University, Changsha, Hunan, China

  • 2. School and Hospital of Stomatology, Wenzhou Medical University, Wenzhou, Zhejiang, China

Article metrics

View details

23

Citations

7,1k

Views

1,7k

Downloads

Abstract

Synovial sarcoma (SS) is a high-grade soft-tissue sarcoma that occurs predominantly in older children and young adults in their thirties. It is usually very challenging to diagnose and treat synovial sarcoma in the head and neck region. The purpose of this review is to investigate the clinical manifestations and different treatment methods in the management of primary synovial sarcoma of the head and neck. HNSS has an aggressive nature and poor prognosis. Surgical resection, radiotherapy, and chemotherapy are the primary treatment methods. Typically, surgical resection with negative margins remains the foundation of therapy, which is not very easily achieved in the head and neck due to its complex anatomical structure and the presence of many blood vessels and nerves. However, synovial sarcoma has a high recurrence rate, so aggressive management and close follow-up are warranted for the optimal outcome.

Introduction

Jernstrom (1954) first described synovial sarcoma (SS) in 1954. SS is a soft tissue malignancy harboring t (X; 18), resulting in the fusion of two genes SS8 (at 18q11) and SSX (1, 2, or 4 at Xp11), forming the gene fusion product SS18–SSX (Stacchiotti and Van Tine, 2018). It primarily affects young adults in their thirties and most frequently occurs in the para-auricular regions of the extremities (70%), followed by the trunk (15%), and least common in the head and neck region (5%–7%) (Sultan et al., 2009; Stacchiotti and Van Tine, 2018). SS of the head and neck (HNSS) is a rare, aggressive malignant tumor with an unpredictable prognosis and is prone to recurrence after treatment (Kumar et al., 2020). The most common site of HNSS is the hypopharynx (Pai et al., 1993). However, HNSS also arises from other sites, including the oropharynx (Herrero Laso and Varela Duran, 1998), nasopharynx (Nakahira et al., 2013), trachea (Reilly and Johnston, 2010), TMJ (Xia et al., 2020), mandible, tongue, paranasal sinuses, floor of the mouth, buccal mucosa (de Araujo and Monteiro, 1989; Mahesh et al., 2013), maxillary sinus (Hannoun et al., 2021), ethmoid sinus (Jain et al., 2018), parotid gland (Grayson et al., 1998), soft and hard palate (Massarelli et al., 1978; Ferlito et al., 1981; Doubi et al., 2019), gingiva (Rao et al., 2014), retromolar area (Meer et al., 2003), and suboccipital region (Karydakis et al., 2018).

According to the International Classification of Diseases for Oncology (ICD-O), SS is divided into three distinct histologic subtypes: monophasic SS, biphasic SS, and poorly differentiated SS (Fiore et al., 2021). Figure 1 shows hematoxylin and eosin staining of the three histologic variants of SS. Other variants include myxoid SS and ossifying/calcifying SS (Shukla et al., 2003; Alabdulaaly et al., 2021). Monophasic SS contains uniform spindle cells, biphasic SS consists of epithelial cells arranged into glandular structures with spindle cells arranged into fascicles, and spindles and round blue cells characterize poorly differentiated SS (Jayasooriya et al., 2016). The monophasic subtype and the biphasic subtype are the two most common subtypes, while the epithelioid cell subtype is rare. Histologically, SS comprised varying proportions of spindle and epithelial cell components. Due to the variable cellular and architectural morphology and resemblance to other neoplastic processes common to the region, the histopathological diagnosis of SS is very challenging (Crowson et al., 2015). Immunohistochemistry plays a crucial role in histological diagnosis. SS is positive for epithelial markers, including cytokeratin, epithelial membrane antigen (EMA), and vimentin. SS is usually unfavorable for CD34 and FLI-1 (Madabhavi et al., 2018).

FIGURE 1

FIGURE 1

Hematoxylin and eosin staining of the three histologic variants of synovial sarcoma (SS). (A,B) Slides of monophasic SS, made of spindle cells with moderate cytologic atypia and differentiated areas of variable cellularity. (C,D) Slides of biphasic SS composed by glandular-like structures with spindle cells without nuclear atypia. (E,F) Slides of poorly differentiated SS in its Ewing-like variant, with the presence of rosette-like structures (magnification: ×20).

The causes and risk factors of SS remain unclear. Researchers have found that in radiotherapy of other cancers, specific inherited gene defects can increase the possibility of getting SS (Ulusan et al., 2005). Furthermore, other studies suggested that SS can be derived from undifferentiated cells, neural crest stem cells, pluripotent mesenchymal cells, and other parts of the body (Carrillo et al., 1992; Machen et al., 1999; Sturgis and Potter, 2003; De Logu et al., 2020). This review about HNSS was written to understand better different treatment methods of SS in the head and neck region in many cases reported before due to the rarity of the disease and lack of data. It is imperative to know how to manage and treat HNSS to improve the health status of patients suffering from SS in the head and neck region.

Synovial sarcoma in laryngeal and pharyngeal regions

The first case of HNSS, which occurred in the pharynx, was described in 1954 by Jernstrom (1954). It is also the most common site HNSS (Pai et al., 1993). The most common signs and symptoms of SS in the laryngeal and pharyngeal region among patients are hoarseness of voice because of proliferative growth involving the vocal cord and aryepiglottic fold with impaired mobility (Kumar et al., 2020), hemoptysis (Papaspyrou et al., 2003; Madabhavi et al., 2018), dyspnea, dysphagia, mass in the neck region, breathing difficulties, and pain. Sometimes the patients are misdiagnosed, such as fibroadenoma or benign tumor, because of the rarity of SS in the head and neck region and lack of clinical and imaging information (Danninger et al., 1994; Wigand et al., 2018; Kaoutar et al., 2021). CT, MRI, and PET-CT can be used in the examination of the patients, and smaller-size SS often shows similar imaging features similar to benign tumors displayed by CT or MRI (Hirsch et al., 1997; Rangheard et al., 2001; Hongzhi Quan et al., 2017).

As shown in Table 1, surgery is the principal treatment modality for synovial sarcoma of the larynx and pharynx, including partial or complete laryngectomy, partial laryngectomy, endoscopic resection, neck dissection, laser endoscopic resection, and CO2 laser excision (Pruszczynski et al., 1989; Capelli et al., 2007). Neck dissection is unnecessary if the tumor does not involve the lymph node (Meer et al., 2003). In some cases, surgery is performed following radiotherapy and chemotherapy, while others undergo surgery followed by radiotherapy without chemotherapy, depending on the patient’s physical status and the physician’s advice. From Table 1, we can see that numerous patients underwent laser endoscopic resection, laryngectomy neck dissection, extended total laryngectomy, and CO2 laser excision, followed by radiotherapy and chemotherapy. Some chemotherapy agents are ifosfamide, adriamycin, cisplatin, actinomycin D, vincristine, dacarbazine, doxetaxel, rh-endostatin, dosorumin, and others (Shein et al., 2021). Table 1shows that the patient underwent postoperative radiotherapy delivering 60 Gy in 30 fractions over 6 weeks, with bilateral prophylactic nodal irradiation to 50 Gy (Holtz and Magielski, 1985). Then, the patient was administered four cycles of doxorubicin and ifosfamide chemotherapy. Twelve months after the initial diagnosis, there was no evidence of recurrence on endoscopy (Madabhavi et al., 2018). In most cases described as follows after treatment of SS, the recurrence rate is quite low, and the patients were cured.

TABLE 1

ReferenceAge/sexLocationSize (cm)Signs and symptomsTypeTreatmentFollow-up
Papaspyrou et al. (2003)16/MRight aryepiglottic fold4 × 3 × 3Dysphagia for 3 mo accompanied with hemoptysis, lost 6 kg in 2 mo, and change of voice in the past 15–20 daysBiphasicLaser endoscopic recs + RNED after 2 years
Madabhavi et al. (2018)31/MLeft arytenoid and left pyriform fossa8 × 4 × 3Hoarseness of voice since 5 weeksUnkS, post-operative R and CNED after 12 mo
DPC and MacGregor (2012)11/MRight aryepiglottic foldUnkUnkUnkPre-operative C + R and total laryngectomyNED after 6 years
Hongzhi Quan et al. (2017)17/MRight neck8 × 6.5UnkBiphasicSurgical resectionDisease-free more than 18 mo
Pruszczynski et al. (1989)28/FLeft aryepiglottic fold and false cord2 × 3Progressive inspiratory stridor of 6 mo and a change of voice of 2 mo and progressive dysphagiaMonophasicEndoscopic recs + RNED after 3 years
Ferlito et al. (1981)28/MRight aryepiglottic fold and epiglottis2.5 × 3Progressive dysphagia and intermittent right otalgia for 2 moBiphasicR pre and post-operative, supraglottic, laryngectomy, and right neck dissectionNED after 16 years
Danninger et al. (1994)53/MRight aryepiglottic fold and pyriform sinusUnkUnkUnkTotal laryngectomy and neck dissection + RNED after 16 mo
de Almeida-Lawall et al. (2009)68/FCricoid cartilageUnkSlowly enlarging neck mass for 5 mo and difficulty in breathing over the last 2 weeksBiphasicExtended total laryngectomy and neck dissection
Bilgic et al. (2003)24/MLeft aryepiglottic fold, epiglottis, and left arytenoid3 × 2.5 × 0.7Changing of his voice and dysphagia for several moBiphasicHemilaryngectomy, total laryngectomy, neck dissection, and R + CRecurrence after 1 year Lung metastasis after 20 mo NED after 3.5 years
Wigand et al. (2018)26/MEpiglottis2.42 × 2 × 1.5Suffered from insidious and slowly progressive odynophagia for 5–6 moBiphasicLaser endoscopic resection neoadjuvant C, partial laryngectomy, and postoperative R + CRecurrence after 6 weeks NED after 20 mo
Capelli et al. (2007)57/MLeft laryngeal ventricleUnkDysphonia for few moMonophasicCO2 laser excisionNED after 14 mo
Fonseca et al. (2014)23/FPharyngeal tumor in the left posterolateral wall near the base of the tongue5.3 × 3.9 × 2.2Dysphagia and difficulty of breathing for 8 mo, resulting in progressive worsening and emergence of snoring, muffled voice, and local painUnkEndoscopic pharyngectomy was used to excise the tumor. C + R1 year postoperatively, the patient continues with locoregional control without recurrence
Kaoutar et al. (2021)23/FPosterolateral pharyngeal wall6Cervical algia and left otalgia since 1 yearUnkC + RUnk
Holtz and Magielski (1985)16/MMid-line above the hyoid bone6 × 4 × 4Sore throat, fever, and a mid-line suprahyoid mass. Midline enlargement above the hyoid bone persistedBiphasicS + R (6,700 rad) given over 8 weeks. 12 mo C course of monthly vincristine, dactinomycin, cyclophosphamide, roentgenographic, and hématologic6 mo later, metastasis was detected at the right pericardiophrenic angle involving the lower lobe of the right lung, the diaphragm, and the pericardium. Patient died 37 mo

Reported cases of laryngeal and pharyngeal synovial sarcoma.

Unk, unknown; Recs, resection; S, surgery; R, radiotherapy; C, chemotherapy; mo, month; NED, no evidence of disease.

Synovial sarcoma of the oral cavity (TMJ, jaw, and tongue)

SS of the oral cavity region is not very common compared to that of the pharyngeal and laryngeal regions. Based on literature, the commonly affected sites of the oral cavity include the jaw, TMJ, and tongue. Table 2 shows SS of the oral cavity (TMJ, jaw, and tongue) (Maxymiw and Wood, 1990; Tilakaratne, 2006; Wang et al., 2008). The clinical symptoms of SS in the TMJ include pre-auricular mass, mouth opening limitation, discomfort in the TMJ, trismus, pain, and swelling in the face (Allias-Montmayeur et al., 1997). SS in the TMJ region may often be misdiagnosed as temporomandibular disorder (TMD) or other benign neoplasms due to the typical slow growth and signs and symptoms (Mostafapour and Futran, 2000). Differential diagnosis, including primary parotid tumor, should also be considered. Before surgery, CT scan and panoramic radiography can also be very helpful in revealing the size and location of the tumor (Bukawa et al., 2007). The ratio of occurrence of SS in males to females in the TMJ region is 8:5. In the current review, surgical excision in the TMJ region was performed in all cases. Local excision was performed through a standard parotid incision with temporal extension (Madabhavi et al., 2018). The metastasis rate of the lymph node is 10%–20%, and prophylactic cervical lymph node dissection is not necessary (Kartha and Bumpous, 2002). In the TMJ region, radical excision with negative margins is not always successful due to the complex anatomical structure. In such cases, surgical excision with adjuvant radiation has shown positive effects and an improved overall survival rate in patients (Stadelmann et al., 1995; Harb et al., 2007). Although the effectiveness of chemotherapy is still controversial, it has been tried in some cases (White et al., 1992; Meer et al., 2003; Luo et al., 2007; Al-Daraji et al., 2009; Nomura and Kishimoto, 2014). Patients with a tumor 5.0 cm in diameter had a higher risk of local tumor recurrence, distant metastasis, and mortality in HNSS (Gopalakrishnan et al., 2017). Other prognostic factors include age, TMN stage, surgical margin, and therapy modality.

TABLE 2

ReferenceAge/sexLocationSize (cm)Signs and symptomsTypeTreatmentFollow-up
Xia et al. (2020)32/FTMJ region2.9 × 2.5 × 3.4Pre-auricular mass, mouth opening limitation, and tendernessBiphasicS + R + C6 mo NED
Bukawa et al. (2007)67/MTMJ region5 × 4.2 × 3Chronic discomfort, trismus, and TMJ painMonophasic epithelialS24 mo died of other disease
Mostafapour and Futran (2000)23/FTMJ region3 × 4 × 3TMJ syndrome, mild trismus, a right infra- temporal non-tender mass, and decreased sensation along the third division of the right trigeminal nerveMonophasicS + R54 mo alive NED
Mostafapour and Futran (2000)35/FTMJ regionUnkTMJ pain and left facial swellingMonophasicS + R18 mo DOD
Wang et al. (2008)32/MTMJ condyle process5 × 4Pre-auricular mass and mouth opening limitationBiphasicSUnk
Luo et al. (2007)21/FTMJ region4 × 3Tender mass over the right pre-auricular region, discomfort over TMJ, tenderness, and mouth opening limitationBiphasicS + R + C60 mo and NED
White et al. (1992)57/MTMJ regionUnkTMJ pain, right posterior open bite, slight swelling, and mandibular deviationBiphasicS + R + C15 mo DOD
Al-Daraji et al. (2009)61/MTMJ region1UnkMonophasicS18 mo
DOD
Al-Daraji et al. (2009)35/FCoronoid process TMJ4UnkMonophasicS + R + C201.6 mo
Alive and NED
Al-Daraji et al. (2009)22/MTMJ region5 × 4UnkMonophasic + poorly differentiatedS9.6 mo
DOD
Allias-Montmayeur et al. (1997)39/MTMJ region2 × 2Pre-auricular swelling, mouth opening limitation, and mandibular deviationBiphasicS5 mo alive NED
Stadelmann et al. (1995)49/MTMJ region3 × 1.5 × 1.5Painless pre-auricular mass and chronic and severe TMJ painBiphasicS + R9 mo alive NED
Nomura and Kishimoto (2014)17/MTMJ region5.5Pain in the TMJUnkS + R + C62 mo DOD
Teixeira et al. (2021)22/MLesion, extending from the left condyle to the mandibular bodyUnkPain in the region of the left mandibular body and ramusMonophasicSLast 2 years
NED
Granowetter et al. (2006)11/MMandibleUnkLeft lower jaw pain and increasing difficulty in eating due to the inability to fully open his mouthMonophasicC (vincristine, actinomycin-D and cyclophosphamide, and ifosfamide, vincristine, and doxorubicin) +R + S3 years alive
Tilakaratne (2006)76/MMandibleUnkProgressive swelling in the left side of his face of 1 mo durationMonophasicHemimandibulectomy with levels I–III cervical lymph node dissectionPatient died after 2 mo (extensive metastasis to the lungs)
Tao et al. (2011)20/FMandibleUnkRecurring swelling in the left posterior regionMonophasicS (mandibulectomy and lymph node dissection) +R (4,000 cGy), for 1 mo1 year alive
Teeth, without pain, but she felt alveodental suppuration
Tilakaratne (2006)29/FMandibleUnkBony hard swelling over the right ramous of the mandible for 2 mo and gradually increase in sizeMonophasicS2 years alive
Maxymiw and Wood (1990)32/FMaxillaUnkRight facial massBiphasicC + RDead
Alabdulaaly et al. (2021)14/FTongue, floor of the mouth, and lingual gingiva of the anterior mandibular teeth7.4 × 4.7 × 5.6Painful tongue mass growing over past 3 years and difficulty eating solid food. Loss of ability to speak and unable to close her lipsMonophasic and calcifyingR (75 Gy) + C (doxorubicin, ifosfamide, and pazopanib)13 mo. Patient alive with disease. NEM
Villaroel-Salinas et al. (2012)31/FBased on the lateral pharyngeal wall and the base of the tongue3.4 × 2.3Progressively growing tumor in the base of the tongueMonophasicSUnk
Sharma and Mehan (2019)22/MBase of the tongueUnkUnkMonophasicUnkUnk
Novotny and Fort (1971)21/MBase of the tongue3.5“Fullness in the throat” for 1 mo + difficulty in speech + slight hoarseness + difficulty in swallowing, with sticking of food and frequent chokingMonophasicRNED (2 years)
Bridge et al. (1988)31/MBase of the tongue2.5UnkBiphasicSUnk
Carrillo et al. (1992)13/MLateral tongue (left)1.0Swelling in the leftBiphasicSPatient is alive and well 1 year following excision
Lateral aspect of the tongue
Su et al. (2018)49/MPosterior one-third (left)UnkPainful bleeding mass located in the left side of the tongue of 4 mo durationBiphasicSPatient remains Symptom-free 2 years postoperatively
de Almeida-Lawall et al. (2009)26/MPosteriolateral aspect of the tongue (right)1UnkBiphasicS18 mo, patient well, with no signs of tumor activity
Su et al. (2018)35/MPosterior one-third (left)UnkMildly painful and non-mobileUnkS + REvery 2 mo for 2 years and then every 6 mo for 2 years
Lump on the left side of his tongue 1 year
Engelhardt and Leafstedt (1983)25/MMass in the right tonsil, attached to the anterior tonsillar pillar and at the tongue base5 × 3Discomfort in the posterior oral cavityUnkS (tracheostomy), and reconstruction via transmandibular symphysis osteotomyNED (38 mo)
Bridge et al. (1988)31/MRight base of the tongue with encroachment on the epiglottis2.52-month sore throat, intermittent otalgia, dyspnea, and occasional hemoptysisBiphasicLaryngectomy with a right radical neck dissectionUnk
Sought medical attention after experiencing a sudden choking sensation and coughing up an ovoid mass of necrotic tissue
Approximately 2.5 cm in diameter
Sharma and Mehan (2019)74/FRight lateral border of the tongue5 × 1 × 3Dysphagia (3 mo)MonophasicS + RDisease-free
During 2 years of follow up

Reported cases of the oral cavity (TMJ, jaw, and tongue).

Unk, unknown; Recs, resection; S, surgery; R, radiotherapy; C, chemotherapy; mo, month; NED, no evidence of disease; DOD, died of disease.

SS in the maxilla and mandible is infrequent compared to that in the TMJ. In this region, SS is usually diagnosed in young female patients, with the mandible and maxilla equally affected (Liu et al., 2015) (three males and three females). Table 2 shows the clinical symptoms of SS of the jaw, including painful swelling, limitation in mouth opening, eating difficulty, and swelling of the face. The diagnosis of intraoral SS and radiographic examination are essential steps used to localize and identify the lesion such as in Table 2 intraoral examination, an expansion of the cortical bone was noticed in the vestibular and lingual regions of the left mandible, and radiographic examination showed the presence of an expansive and multiocular radiolucent lesion extending from the left condyle to the mandible body (Granowetter et al., 2006; Teixeira et al., 2021). The clinical diagnostic hypotheses were ameloblastoma or malignant neoplasm. A combination of clinical, histologic, and immunohistochemical approaches can be used to support the diagnosis of SS in the jaw.

In the jaw region, biopsy is usually performed during surgical excision followed by microscopic evaluation immunohistochemistry. Regarding the treatment for SS of the jaw, wide surgical excision is necessary to obtain a clear margin followed by adjuvant radiotherapy, and chemotherapy is the recommended treatment modality (Bergh et al., 1999; Tao et al., 2011; Wushou and Miao, 2015). Primary intraosseous SS of the jaws has a high recurrence rate and tumor-related death (Teixeira et al., 2021). As we can observe from Table 2, three patients died (jaw region). Thus, long-term follow-up is required for early detection of recurrence.

The tongue is the relatively frequently affected intraoral site of SS (Novotny and Fort, 1971; Bridge et al., 1988; Fujimoto et al., 2003; Villaroel-Salinas et al., 2012), and it was first described as a site of SS occurrence by Mir-Abedy (1962). Common signs and symptoms of SS of the tongue include pain in the tongue area, eating difficulties, loss of ability to speak, inability to close lips, hoarseness, frequent choking, sore throat, fever, and swelling. Most cases reported in Table 2 are biphasic subtypes than monophasic, and very few cases are of calcifying SS (Alabdulaaly et al., 2021). In our review, the first case in the tongue area is a monophasic and calcifying subtype (Alabdulaaly et al., 2021). Due to its rarity, diagnosis of the disease is complicated disease. In this specific case, we can observe histologically (monophasic and calcified subtype) that there was an infiltrative tumor composed of a diffuse and highly cellular proliferation of the spindle cells with a ringbone pattern, collagenous stroma, extensive calcification, and numerous dilated vessels (Alabdulaaly et al., 2021). MRI is of significant importance in determining the actual size and location of the tumor in the tongue. As we can observe from Table 2, MRI of the head and neck revealed the presence of a large tumor occupying the left side of the tongue (Su et al., 2018). The tumor was classified as stage IIB based on NCCN guidelines. Tumor of this stage should primarily be managed by en bloc resection to obtain oncologically appropriate margins, followed by radiation therapy and adjuvant chemotherapy (Su et al., 2018). After the surgical procedure, the incision healed well and his tongue movement improved. MRI revealed no enlarged lymph nodes in the neck (Su et al., 2018). Treating SS in the tongue includes excision (composite resection of the tonsil and tongue base, radical neck dissection, tracheostomy, and reconstruction via transmandibular symphysis osteotomy followed by (with or without) radiotherapy (75 Gy) and chemotherapy (doxorubicin, ifosfamide, and pazopanib) (Engelhardt and Leafstedt, 1983).

Synovial sarcoma of the paranasal sinus tract

Trible (1970) first described a patient with SS that metastasized to the sphenoid sinus. SS of the sinonasal tract is more common in young adults but can occur at any age, with slight male predominance. The most common signs and clinical symptoms are nasal obstruction, epistaxis, and rhinorrhea. Moreover, the cause of SS arising from the sinonasal tract is unclear (Jain et al., 2018; Lin et al., 2021). Diagnosis of SS of the sinonasal tract remains challenging because of the sheer number of differentials that may present and behave like SS. During diagnosis, the physician should pay attention to some clinical indicators, such as the relatively rapid progression of the symptoms and “disrespecting the anatomical distribution” toward the possible malignant nature of the disease (Subramaniam et al., 2012). Anterior rhinoscopy can be very helpful to determine the exact size and location of the tumor. Ophthalmic examination is also performed in order to determine whether the tumor affects vision and eyeball movements (Jain et al., 2018). CT is also an important tool in verifying whether ethmoid, sphenoid, and frontal sinuses are involved (Jain et al., 2018). In order to avoid misdiagnosis, radiology and clinicopathological features play a significant role in diagnosing SS of the sinonasal tract (Lin et al., 2021). An MRI can be beneficial in the determination of the nature of the defect as it can demonstrate a heterogeneously enhancing lesion along with the surrounding structures, and CT can indicate the nature of the nasal mass (Tateishi et al., 2004).

Moreover, the histopathological study generally confirms the diagnosis, and the primary treatment is complete surgical excision including craniotomy, endoscopic resection, and total maxillectomy (Sun et al., 2003; Gallia et al., 2005; Hannoun et al., 2021). Resection with a negative margin is very difficult to achieve in the paranasal sinus, especially endoscopic sinus resection, and due to the complexity of the anatomical structures, the surgeon should try to achieve a precise border resection if possible. The prognosis of the disease can be affected by some factors, such as the size of the tumor, marginal clarity, mitotic activity, neurovascular invasion, and the ki67 proliferation index (Singer et al., 1996). Table 3 shows that one of the patients underwent partial medial maxillectomy; complete ethmoidectomy, except for cribriform plate/anterior cranial fossa resection; and partial middle turbinectomy. After surgery, 3 weeks later, CT and MRI showed inflammation with no gross residual tumor. Due to the absence of tumor-free resection margin and high-grade sarcoma, the patient underwent ifosfamide-based chemotherapy and external beam radiotherapy of 60–65 Gy (Jain et al., 2018). The central problem when adopting this approach is that it can cause cosmetic and functional defects when trying to achieve precise border resection in regions of complex anatomical anatomy in the parasinus region. Despite all this, it has a high recurrence rate within 2 years (Hoffman et al., 2004; Colville et al., 2005; Nielsen et al., 2015), especially in the skull base and paranasal sinus SS (Owosho et al., 2017), depending on the tumor stage, size, and site (Harb et al., 2007). After surgery, it is recommended to perform regular endoscopic and radiological examinations during the follow-up period. Concerning radiology, CT is more advantageous in detecting tumor recurrence but should be advised after 12 weeks after surgery to avoid false positive results (Wong et al., 2014).

TABLE 3

ReferenceAge/sexLocationSize (cm)Tumor stageTypeSigns and symptomsTreatmentFollow-upOutcome
Sun et al. (2003)54/MMaxillary sinusUnkUnkBiphasicRight-sided nasal obstruction and cheek pressure for 5 weeksS (total maxillectomy)NED (45 mo)
Jain et al. (2018)36/FEthmoid2 × 2 × 2.5T2N0M0Monophasic; negativeLeft nasal obstruction and epistaxis since 3 monthsEndoscopic excision followed by radiotherapyPostoperative radiotherapy (IMRT) 45Gy/25 fractions and boost 20Gy/10 fractions to the tumor region; no distant metastasisNED (6 mo)
Lin et al. (2021)79/FNasal cavity, ethmoid, and frontal and maxillary sinusUnkUnkMonophasicNasal obstruction, epistaxis, hyposmia, and exophthalmosS + C + R8–40 mo imaging follow-upTumor recurred within 2 years
Hannoun et al. (2021)53/MMaxillary sinus3.8 × 2.8 × 4.2T4aN0M0MonophasicLeft-sided hearing loss accompanied by a left-sided nasal block and a vague facial and dental painS + RMonthly basis for the first year, and yearly thereafter; with no recurrence 5 mo after therapy
Wong et al. (2014)80/FEthmoidUnkT2N0M0Monophasic6-mo history of persistent right-sided epistaxisS (endoscopic recs)Local recurrence at 3 mo; endoscopic excision followed by R; distant metastasis: brain and neck nodeDied at 9 mo
Saito et al. (2018)53/MMaxillary sinusUnkUnkBiphasicLeft nose obstruction over the previous couple of yearsS + RMonthly basis for the first year, and yearly thereafter; with no recurrence 5 months after therapy
Saito et al. (2018)53/MLeft maxillary sinus5 × 5.8UnkBiphasicLeft nose obstruction over the previous couple of yearsC + R12 moFree of disease after 12 mo of treatment
Kartha and Bumpous (2002)24/FEthmoid6 × 4×3T4N2aM0MonophasicRecs, R (86 Gy)Recurrence at 1 mo; C and RT (8,600 cGy) after recurrence; distant metastasis; pulmonary, brainDied at 9 mo
Dhiman et al. (2021)43/FEthmoidUnkUnkUnkProgressive nasal obstruction and swelling in the medial canthal region on the left side for the last 4 moTumor-free Resection + ifosfamide-based C + R of 60–65 GyPatient remained asymptomatic for 1 year, but later, she was lost to follow-up6 mo later, a tumor recurrence in the left orbit
Dhiman et al. (2021)82/FEthmoidUnkUnkUnkRight nostril obstruction, epistaxis, external nasal deformity associated with swelling of the right upper eyelid, double vision, and headacheR based on advanced stage and age of the patient, + ifosfamide-based CDied after 6 weeks of diagnosisDied after 6 weeks of diagnosis
Subramaniam et al. (2012)45/MSphenoid3.3UnkUnkEpistaxis and blurred vision for a few weeksS (biopsy)UnkUnk
Gallia et al. (2005)44/MFrontal3.3 × 2.5UnkMonophasicRight-sided proptosisS (craniotomy)2 moNED (2 mo)
Ulusan et al. (2005)52/FNasal Septum1.5 × 1.5UnkUnkProgressively enlarging mass in her left nasal cavity of 1 year durationS (recs)18 moNED

Reported cases of synovial sarcoma in the paranasal sinus tract.

Unk, unknown; Recs, resection; S, surgery; R, radiotherapy; C, chemotherapy; mo, month; NED, no evidence of disease.

Synovial sarcoma of the orbital and ocular region

Orbital and ocular SS is exceedingly rare. Table 4 shows common signs and symptoms of patients suffering from SS of the orbital and ocular region: growth of the mass, painless exophthalmia, orbital swelling, proptosis, inflamed conjunctiva, limited ocular motility, and painful cystic lesion. In the ocular region, ophthalmologic examination is of great importance in order to analyze the exact size and location of the lesion (Portelli et al., 2019). However, we should also be clear about the differential diagnosis before making a definite conclusion. (Table 4) In our reported case, the histological differential diagnosis in the last case includes malignant peripheral nerve sheath tumor (MPNST), leiomyosarcoma (LMS), fibrosarcoma (FS), and solitary fibrous tumor (SFT) (Portelli et al., 2019). The cells were in a sheet arrangement and vague fascicles, with alternating hypercellular and hypocellular myxoid areas, and FS-like areas were absent. Similar to synovial sarcoma, malignant peripheral nerve sheath tumors can express S100 protein, EMA, CK7, CK19, TLE1, and SOX10. Furthermore, CD34 is absent in SS. In the last case reported, the neoplasm was negative for CK7, CK19, SOX10, CD34, and muscular markers. Cell fascicles were more prolonged, loose, and ample than intersecting.

TABLE 4

ReferenceAge/sexLocationSigns and symptomsTypeTreatmentFollow up
Portelli et al. (2019)24/FLeft superonasal orbital region1 year history of gradually growing occasionally painful cystic lesion in the left superonasal orbital regionMonophasicSurgical intervention with a complete removal of the massThe patient is free of recurrences and metastases after 20 mo
Votruba et al. (2002)29/MConjunctiva, medial canthus, and right eye. 1-cm mass adherent to the medial rectus muscle4-mo-hst of growing mass in the conjunctivaMonophasicComplete excision with close marginsUnk
Hartstein et al. (2006)14/MLeft orbit and inferotemporally1-mo-hst of painless proptosis of the left eyeBiphasicTotal exenterationRecover and without recurrences after 18 mo
Ratnatunga et al. (1992)21/FLeft orbit: 3 cm × 1.5 cm × 1.5 cm subconjunctival mass, adherent to the medial rectus muscle and extending posteriorly into the retrobulbar region5-year-hst of progressively enlarging, painless mass, and limited adductionBiphasicIncomplete excisionUnk
Ratnatunga et al. (1992)42/FLeft orbit: about 2-cm mass, adherent to the tendon sheath of the superior oblique muscle8-mo-hst of left-sided orbital swellingBiphasicUnkUnk
Shukla et al. (2003)32/FLeft orbit: 4 × 2.5-cm firm, fixed mass, encroaching up to the cornea5 years of recurrent swelling and pain around her left eye, diplopia, and VA: 6/60BiphasicPartial excision; adjuvant RT.Unk
Liu et al. (2012)1.5/FLeft upper eyelid, nasal portion, and adherent to medial rectus muscle1 mo of painless swelling in her left eyelid, proptosis, inflamed conjunctiva, and limited ocular motilityPoorly differentiatedOrbitotomy; adjuvant CT.No recurrences and mts after 1 year
Ito et al. (2015)48/FLeft eyeball, intraocular, behind the iris, 1.5 cm × 1 cm × 0.7 cm2 mo of left eye visual defect; retinal detachment surgery, vitrectomy, and insertion of silicon explant 24 years beforePoorly differentiatedEnucleation of the eyeTumor-free after 6 mo
Stagner et al. (2017)31/FLeft inferior orbitFullness in her temporal left lower eyelid, periorbital pain, and hemifacial pain for more than a decade; proptosis, upward displacement of the globe, and eyelid proptosisPoorly differentiatedSubtotal excisionRecover after 1 year
Adjuvant RT.
Xu and Chen, (2017)6/FRight orbit and temporal portion1 week of gradual painless proptosis of right eyeMonophasicTotal excisionRecover after 1 year
Adjuvant CT.

Reported cases of synovial sarcoma of the orbital and ocular region.

Unk, unknown; Recs, resection; S, surgery; R, radiotherapy; C, chemotherapy; mo, month; NED, no evidence of disease.

Referring to Table 4, surgical excision (orbitotomy, partial, and total enucleation of the eye) is the most effective treatment for the disease (Ito et al., 2015). In some cases, like case 2 (Votruba et al., 2002), complete excision was performed, but in other cases, complete resection is not possible due to the complex anatomical structure around the orbital region (Ratnatunga et al., 1992). Sometimes, the patients undergo two surgical interventions due to the complexity of the disease. In one of the following cases, the lesion was partially removed because complete removal was not possible and sent for definitive histopathologic examination. Histological examination showed a spindle cell proliferation, composed of relatively small and fairly uniform metastases. Then, a second surgical intervention with a complete removal of the mass was then undertaken, without ocular complications. The patient is free of recurrences and metastases after 20 months of follow-up (Portelli et al., 2019). In some cases as reported in Table 4, radiotherapy and chemotherapy are also used after surgical excision of SS to minimize the recurrence rate of the disease (Shukla et al., 2003; Hartstein et al., 2006; Liu et al., 2012; Stagner et al., 2017; Xu and Chen, 2017).

Synovial sarcoma in other rare sites of the head and neck (occipital and salivary gland)

Synovial sarcoma of the suboccipital region is a sporadic condition in patients. As we can observe from Table 5, a 12-year-old girl presented to the hospital with a painless tumefaction on the right suboccipital region evolving for 5 months (Karydakis et al., 2018), and after undergoing imaging examination, MRI showed an encapsulated spindle formation in the region of the soft tissues of the right suboccipital region, and CT showed that there was only thinning of the bone without erosion. Laboratory results did not show specific features, and the alkaline phosphatase level elevated slightly. The little girl underwent tumor resection. She was in the left lateral position in the operating room and underwent a combination of blunt and sharp dissection. The mass was well-circumscribed with a stiff consistency. The bone underneath the lesion was eroded. Furthermore, the lesion was fibrous and viscous. A few days later, after the surgery, the patient was discharged. Complete surgical excision is the primary treatment for SS of the suboccipital region, and as we can notice, it is tough to diagnose as the condition is infrequent.

TABLE 5

ReferenceAge/sexLocationSigns and symptomsSize (cm)TypeTherapyFollow up
Massarelli et al. (1978)19/MPalateDifficulty in swallowing1.5UnkS + RAlive 1 year
Jay et al. (2008)35/FR parotidSwelling of the right parotid region of uncertain duration with 10 years history of right-sided facial pain and headache5 × 3MonophasicR total conservative parotidectomy36 mo alive
Ploutarchos (Karydakis et al., 2018)12/FRight suboccipital regionPainless mass for 5 moUnkUnkComplete S recsUnk
Mariano et al. (2012)18/MR submandibular glandMass of the right submandibular region that had been present for the past 12 mo10 × 8MonophasicS + R 70 Gy10 mo, alive

Report cases of primary synovial sarcoma in other rare sites of the head and neck.

Unk, unknown; Recs, resection; S, surgery; R, radiotherapy; C, chemotherapy; mo, month; NED, no evidence of disease.

Ultrasonography of the neck is a very important step in the gland region to determine the exact location and size of the lesion. For the diagnosis, the patient underwent fine-needle aspiration biopsy. Table 5shows that a women of age 35 with swelling of the right parotid region of uncertain duration with 10 year history caused by right-sided facial pain and headache was treated with total conservative parotidectomy and was alive for 36 months (Jay et al., 2008). In another case, a young man with mass of the right submandibular gland region that had been present for the past 12 months underwent surgical resection of the submandibular gland and adjuvant radiotherapy to a total dose of 7,000 cGy to prevent recurrence (Mariano et al., 2012). The treatment was effective, with no evidence of the disease. Synovial sarcoma in the palatal region can cause difficulty in swallowing, and the main treatment is usually surgical excision followed by radiotherapy (Sharma and Mehan, 2019).

Discussion

The reviewed literature demonstrates reported cases of SS in different areas in the head and neck region and patients’ diagnosis, treatment method, and prognosis. SS is generally considered a high-grade sarcoma, marked by a poor prognosis. The tumor site can also affect prognosis, with a worse outcome for tumors arising from anatomic sites other than the extremities. Some cases, like SS in the suboccipital region, are even more uncommon, making it much more complicated in terms of diagnosis and treatment.

From this review, we can say that diagnosing SS in the head and neck region is not easy and can be easily misdiagnosed. SS is divided into subtypes: biphasic, monophasic, and poorly differentiated. Nevertheless, as we can observe from Table 2, there are more monophasic subtypes such as monophasic and calcified subtype. Concerning the diagnosis of SS, microscopically, it is not too difficult to diagnose the biphasic subtype of SS but tough to diagnose the monophasic form. In such cases, immunohistochemistry along with molecular studies can be very effective in the diagnosis. We can also conclude that the poorly differentiated subtype is the most challenging diagnosis, mainly when SS occurs in an unusual location. Cytogenetics can also be very useful in the diagnosis of SS. About 90% of SS harbor a specific translocation between the SYT gene on chromosome 18 and either the SSX1 or SSX2 gene on chromosome X. t (X; 18) (p11.2; q11.2) (Bridge et al., 1988; Bellakhdhar et al., 2018). This translocation results in the fusion of SYT genes located on chromosome 18 with highly homologous SSX-1 (SYT-SSX-1), SSX-2 (SYT-SSX-2), and SSX-4 (SYT-SSX-4) genes on the X chromosome (Pai et al., 1993). Genetic testing effectively distinguishes SS from spindle cells and round-cell sarcomas in poorly differentiated tumors. As mentioned in the review, imaging such as CT and MRI is also essential in diagnosing. Sometimes in some cases where the tumor lesion is tiny, the tumor can be misdiagnosed, but it can also be very helpful in determining the nature of the defect; MRI can show an image of the lesion with the invasion of the surrounding structures and the exact size and location of the lesion. However, microscopic and immunohistochemical examination remains the definitive diagnosis for SS in the head and neck region (Eilber and Dry, 2008).

Concerning the treatment of SS in different areas in the head and neck region, we can conclude that surgical excision is the primary treatment modality (Fiore et al., 2021). Surgical treatment includes complete tumor resection, partial resection, cervical lymph node dissection, and flap reconstruction (Bertolini et al., 2003; Wang et al., 2020). As shown in Table 2, surgical resection with negative margins remains the primary mainstay therapy in patients suffering from SS of the TMJ region. In general, wide surgical resection is the first choice for treating SS of the TMJ. There is no standard protocol for the treatment of SS (Bertolini et al., 2003). Wide local excision is usually recommended, and also adjuvant radiation with or without chemotherapy (de Almeida-Lawall et al., 2009). For patients who underwent partial excision or surgical resection with surgical margin involved by the tumor, adjuvant radiotherapy or chemotherapy can be given (Bilgic et al., 2003; Fiore et al., 2021). Radiotherapy has been reported to be effective in controlling the disease (Artico et al., 2004; Wushou and Miao, 2015; Madabhavi et al., 2018), and while chemotherapy effectiveness is controversial, it can be helpful in treating distant metastasis (Vining et al., 2017; Fiore et al., 2021). Table 1 shows that most patients were treated with surgical resection followed by radiotherapy. The role of radiotherapy in treating laryngeal SS is contentious. The complex anatomy, such as vital vascular structures and nerves within the head and neck region, generally compromises the complete surgical excision, and sometimes resection is associated with high positive margins. Radiotherapy has thus been used as an adjunct to surgery to achieve locoregional disease control (Shein et al., 2021). Harb et al., 2007 found that radiotherapy is associated with lower recurrence rates and higher survival, although the results did not achieve significance. Recent studies demonstrate that patients who did not receive radiotherapy showed a worse prognosis than those who did. Naing et al. (2015) reported that radiotherapy is strongly associated with OS and DSS.

In general, in order to optimize overall treatment outcomes, a multidisciplinary, patient-centered approach must be adopted. Few reported cases concerning the specialist care delivered by allied health services include speech pathology, physiotherapy, and psychology. Surgical excision of the larynx and laryngeal dysfunction is associated with reduced quality of life and overall emotion of the patient, especially in young patients suffering from SS of the larynx. Comprehensive airway rehabilitation and psychological support are essential for these patients (DPC and MacGregor, 2012). Usually, after surgery, follow-up is essential to monitor the recurrence rate and increase disease-free survival (Fonseca et al., 2014). Mamelle et al. (1986) reported that postoperative radiotherapy could help reduce local recurrence and is not associated with any improvements in long-term survival. Table 3 shows that, as reported by Wong et al. (2014), the patient declined postoperative radiotherapy treatment, and after 3 months, the disease recurred. Later, the patients underwent surgical excision of the tumor with postoperative radiotherapy. The patients died after 9 months due to metastasis of the brain and neck nodes. Radiotherapy is beneficial in controlling the disease (Jain et al., 2018).

Chemotherapy has been found to have a particular effect on the treatment of HNSS in one case. Santoro et al. (1995) mentioned disease-free and overall survival improvements with ifosfamide and doxorubicin. Nevertheless, due to lack of data, it is tough to figure out the effect of chemotherapy. Sarcoma Meta-Analysis Collaboration found that adjuvant chemotherapy for adults’ localized resectable soft tissue sarcoma improved time to local recurrence and distant recurrence and overall recurrence-free survival (Adjuvant chemotherapy for localised resectable, 1997; Desar et al., 2018). The effect of chemotherapy on pediatric patients is well-defined and has a high response rate (Venkatramani et al., 2021), whereas in adults, the data are insufficient, and its effect is controversial (Al-Hussaini et al., 2011) and is generally defined as low chemosensitive (Trassard et al., 2001; Jacobs et al., 2018). Cytotoxic chemotherapy is often considered in both the neoadjuvant and adjuvant settings for patients with advanced SS. Combined treatment with doxorubicin and ifosfamide represent front-line therapy for SS. The role of chemotherapy is still under refinement and can be considered in patients at high risk of metastasis or in those with advanced disease. Neoadjuvant chemotherapy might be considered in specific situations, for example, as induction therapy to enhance the outcome of surgery in high-risk sarcoma of extremity. It is sometimes tough to perform surgical interaction in the head and neck region. Surgical resection can also cause some complications related to cosmetic and functional deterioration and increase the risk of perioperative complications. In such cases where surgical option is limited, chemotherapy can be used to decrease the tumor size and make the overall therapy more effective, as shown in the case (Saito et al., 2018) in Table 3. However, the effect of chemotherapy is still very unclear due to lack of data and research (Dhiman et al., 2021). More research should be carried out concerning the effect of chemotherapy on SS. Other research shows that directly targeting the fusion oncoprotein can be used as a new treatment method in SS. As we know, the SS18–SSX fusion gene is consistently retained in synovial sarcoma, and synovial sarcoma cells depend on continued SS18–SSX expression throughout the course of the disease. Therefore, it may be more feasible to target the critical oncogenic pathways to induce the development of SS (Nielsen et al., 2015). Many treatment methods have been identified. However, the impact of these strategies in improving SS outcomes is still limited, thus making current and future research strongly needed to improve the survival of patients with SS.

Conclusion

This review aims to familiarize ourselves with the diagnosis, treatment modality, and prognosis of SS in the head and neck region. Misdiagnosis of the disease can delay the diagnosis and treatment of SS. Immunohistochemical analysis might be fundamental in diagnosing SS, especially those suffering from the monophasic and poorly differentiated subtypes. The management principle is still unclear; a multidisciplinary approach is essential in managing HNSS. More research must be carried out concerning chemotherapy’s effectiveness in treating SS to improve the survival rate and control the recurrence rate of the tumor.

Statements

Author contributions

Corresponding author HQ contributed to the conception of the study; first co-author SS performed the data analyses and wrote the manuscript; first co-author YW performed the data analyses and wrote the manuscript.

Funding

This work was supported by the Graduate Reform Programme of Teaching, CSU (512220104).

Acknowledgments

The authors are indebted to many scientists whose research results are cited here.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  • 1

    Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma meta-analysis collaboration. Lancet. 1997;350(9092):16471654.

  • 2

    Al-DarajiW.LasotaJ.FossR.MiettinenM. (2009). Synovial sarcoma involving the head: Analysis of 36 cases with predilection to the parotid and temporal regions. Am. J. Surg. Pathol.33 (10), 14941503. 10.1097/PAS.0b013e3181aa913f

  • 3

    Al-HussainiH.HoggD.BlacksteinM. E.O'SullivanB.CattonC. N.ChungP. W.et al (2011). Clinical features, treatment, and outcome in 102 adult and pediatric patients with localized high-grade synovial sarcoma. Sarcoma2011, 231789. 10.1155/2011/231789

  • 4

    AlabdulaalyL.AlDawoodZ.AfsharS.RahbarR.Al-IbraheemiA.WooS. B. (2021). Calcifying synovial sarcoma of the tongue with SS18 rearrangement: A rare variant in a rare location. Oral Surg. Oral Med. Oral Pathol. Oral Radiol.132 (5), e186e189. 10.1016/j.oooo.2020.08.016

  • 5

    Allias-MontmayeurF.DurrouxR.DodartL.CombellesR. (1997). Tumours and pseudotumorous lesions of the temporomandibular joint: A diagnostic challenge. J. Laryngology Otology111 (8), 776781. 10.1017/s0022215100138617

  • 6

    ArticoR.BisonE.BrottoM. (2004). Monophasic synovial sarcoma of hypopharynx: Case report and review of the literature. Acta Otorhinolaryngol. Ital.24 (1), 3336.

  • 7

    BellakhdharM.ChenitiA.GhammemM.BdiouiA.MestiriS.MeherziA.et al (2018). Laryngeal synovial sarcoma: Report of 2 cases. J. Egypt Natl. Canc Inst.30 (4), 173176. 10.1016/j.jnci.2018.10.002

  • 8

    BerghP.Meis-KindblomJ. M.GherlinzoniF.BerlinO.BacchiniP.BertoniF.et al (1999). Synovial sarcoma: Identification of low and high risk groups. Cancer85 (12), 25962607. 10.1002/(sici)1097-0142(19990615)85:12<2596:aid-cncr16>3.0.co;2-k

  • 9

    BertoliniF.BianchiB.PizzigalloA.TullioA.SesennaE. (2003). Synovial cell sarcoma of the neck. Case report and review of the literature. Acta Otorhinolaryngol. Ital.23 (5), 391395.

  • 10

    BilgicB.MeteO.OzturkS. A.DemiryontM.KelesN.BasaranM. (2003). Synovial sarcoma: A rare tumor of larynx. Pathol. Oncol. Res.9 (4), 242245. 10.1007/BF02893385

  • 11

    BridgeJ. A.BridgeR. S.BorekD. A.ShafferB.NorrisC. W. (1988). Translocation t(X;18) in orofacial synovial sarcoma. Cancer62 (5), 935937. 10.1002/1097-0142(19880901)62:5<935::aid-cncr2820620514>3.0.co;2-e

  • 12

    BukawaH.KawabataA.MuranoA.OnoK.OgawaraK.ShiibaM.et al (2007). Monophasic epithelial synovial sarcoma arising in the temporomandibular joint. Int. J. Oral Maxillofac. Surg.36 (8), 762765. 10.1016/j.ijom.2007.02.014

  • 13

    CapelliM.BertinoG.MorbiniP.ProhM.FalcoC. E.BenazzoM. (2007). CO2 laser in the treatment of laryngeal synovial sarcoma: A clinical case. Tumori93 (3), 296299. 10.1177/030089160709300313

  • 14

    CarrilloR.Rodriguez-PeraltoJ. L.BatsakisJ. G. (1992). Synovial sarcomas of the head and neck. Ann. Otol. Rhinol. Laryngol.101 (4), 367370. 10.1177/000348949210100415

  • 15

    ColvilleR. J.CharltonF.KellyC. G.NicollJ. J.McLeanN. R. (2005). Multidisciplinary management of head and neck sarcomas. Head. Neck27 (9), 814824. 10.1002/hed.20232

  • 16

    CrowsonM. G.LalichI.KeeneyM. G.GarciaJ. J.PriceD. L. (2015). Clinicopathologic factors and adjuvant treatment effects on survival in adult head and neck synovial cell sarcoma. Head. Neck37 (3), 375380. 10.1002/hed.23605

  • 17

    DanningerR.HumerU.StammbergerH. (1994). Synovial sarcoma, a rare tumor of the larynx. Case report and differential diagnostic considerations. Laryngorhinootologie73 (8), 442444. 10.1055/s-2007-997169

  • 18

    de Almeida-LawallM.Mosqueda-TaylorA.Bologna-MolinaR. E.Dominguez-MalagonH. R.Cano-ValdezA. M.Luna-OrtizK.et al (2009). Synovial sarcoma of the tongue: Case report and review of the literature. J. Oral Maxillofac. Surg.67 (4), 914920. 10.1016/j.joms.2008.08.031

  • 19

    de AraujoV. C.MonteiroD. C. (1989). Oral synovial sarcoma: Report of a case. J. Oral Maxillofac. Surg.47 (9), 10011003. 10.1016/0278-2391(89)90389-3

  • 20

    De LoguF.UgoliniF.CaporaliniC.PalombaA.SimiS.PortelliF.et al (2020). TRPA1 expression in synovial sarcoma may support neural origin. Biomolecules10 (10), 1446. 10.3390/biom10101446

  • 21

    DesarI. M. E.FleurenE. D. G.van der GraafW. T. A. (2018). Systemic treatment for adults with synovial sarcoma. Curr. Treat. Options Oncol.19 (2), 13. 10.1007/s11864-018-0525-1

  • 22

    DhimanS.NegiS.MoudgilS.ThakurJ. S.AzadR. K. (2021). Synovial sarcoma of ethmoidal sinus. Surg. J. (N Y).7 (3), e195e198. 10.1055/s-0041-1731634

  • 23

    DoubiA.DoubiM.AlzaherN.TulbahA. (2019). Synovial sarcoma of the hard palate: The third case in the medical literature. Hematol. Oncol. Stem Cell Ther.12 (1), 6063. 10.1016/j.hemonc.2016.12.005

  • 24

    DpcC.MacGregorF. B. (2012). Laryngeal synovial cell sarcoma in an 11 year old boy: Challenges of management and rehabilitation. Int. J. Pediatr. Otorhinolaryngology Extra7 (3), 9799. 10.1016/j.pedex.2012.02.002

  • 25

    EilberF. C.DryS. M. (2008). Diagnosis and management of synovial sarcoma. J. Surg. Oncol.97 (4), 314320. 10.1002/jso.20974

  • 26

    EngelhardtJ.LeafstedtS. W. (1983). Synovial sarcoma of tonsil and tongue base. South Med. J.76 (2), 243244. 10.1097/00007611-198302000-00025

  • 27

    FerlitoA.GaleN.HvalaA.MaseraA.HvAlAA. (1981). Synovial sarcoma of the soft palate in a child: A light and electron microscopic study. J. Laryngol. Otol.95 (2), 197204. 10.1017/s0022215100090605

  • 28

    FioreM.SambriA.SpinnatoP.ZucchiniR.GianniniC.CaldariE.et al (2021). The Biology of synovial sarcoma: State-of-the-Art and future perspectives. Curr. Treat. Options Oncol.22 (12), 109. 10.1007/s11864-021-00914-4

  • 29

    FonsecaA. S.AzevedoA. C.MagalhaesF. M.AndradeN. A. (2014). Synovial sarcoma in head and neck: A case report. Int. Arch. Otorhinolaryngol.18 (1), 8789. 10.1055/s-0033-1361081

  • 30

    FujimotoM.HiragaM.KiyosawaT.MurakamiT.MurataS.OhtsukiM.et al (2003). Complete remission of metastatic clear cell sarcoma with DAV chemotherapy. Clin. Exp. Dermatol28 (1), 2224. 10.1046/j.1365-2230.2003.01109.x

  • 31

    GalliaG. L.SciubbaD. M.HannC. L.RamanS. P.WestraW. H.TufaroA. P.et al (2005). Synovial sarcoma of the frontal sinus. Case report. J. Neurosurg.103 (6), 10771080. 10.3171/jns.2005.103.6.1077

  • 32

    GopalakrishnanV.AminiB.WagnerM. J.NowellE. N.LazarA. J.LinP. P.et al (2017). Synovial sarcoma of the head and neck: A single institution review. Sarcoma2017, 2016752. 10.1155/2017/2016752

  • 33

    GranowetterL.LadasE.TarominaK.RooneyD.KellyK. M. (2006). Integrative tumor board: Pediatric synovial sarcoma. Integr. Cancer Ther.5 (1), 4855. 10.1177/1534735405285950

  • 34

    GraysonW.NaylerS. J.JenaG. P. (1998). Synovial sarcoma of the parotid gland. A case report with clinicopathological analysis and review of the literature. S Afr. J. Surg.36 (1), 3234.

  • 35

    HannounB.HannounI.BaraA.AlassafA.ChattyE. M. (2021). Synovial sarcoma of the maxillary sinus - a rare condition managed with a rationalized surgery. Ann. Med. Surg. (Lond).67, 102538. 10.1016/j.amsu.2021.102538

  • 36

    HarbW. J.LunaM. A.PatelS. R.BalloM. T.RobertsD. B.SturgisE. M. (2007). Survival in patients with synovial sarcoma of the head and neck: Association with tumor location, size, and extension. Head. Neck29 (8), 731740. 10.1002/hed.20564

  • 37

    HartsteinM. E.SilverF. L.LudwigO. J.O'ConnorD. M. (2006). Primary synovial sarcoma. Ophthalmology113 (11), 20932096. 10.1016/j.ophtha.2006.04.037

  • 38

    Herrero LasoJ. L.Varela DuranJ. (1998). Oropharyngeal synovial sarcoma. Report of one case. Otorrinolaringol Ibero Am25 (4), 353359.

  • 39

    HirschR. J.YousemD. M.LoevnerL. A.MontoneK. T.ChalianA. A.HaydenR. E.et al (1997). Synovial sarcomas of the head and neck: MR findings. AJR Am. J. Roentgenol.169 (4), 11851188. 10.2214/ajr.169.4.9308488

  • 40

    HoffmanH. T.RobinsonR. A.SpiessJ. L.BuattiJ. (2004). Update in management of head and neck sarcoma. Curr. Opin. Oncol.16 (4), 333341. 10.1097/01.cco.0000127880.69877.75

  • 41

    HoltzF.MagielskiJ. E. (1985). Synovial sarcomas of the tongue base. The seventh reported case. Arch. Otolaryngol.111 (4), 271272. 10.1001/archotol.1985.00800060095016

  • 42

    Hongzhi QuanM. K.LiuY.TangZ.FangL. (2017). Relapse of synovial sarcoma in head and neck after a six-year disease-free period: A case report and literature review. Int. J. Clin. Exp. Med.10 (12), 1670916714.

  • 43

    ItoJ.SuzukiS.YoshidaA.MoriT. (2015). Primary intraocular synovial sarcoma in the post retinal detachment operative state. BMJ Case Rep.2015, bcr2015209919. 10.1136/bcr-2015-209919

  • 44

    JacobsA. J.MorrisC. D.LevinA. S. (2018). Synovial sarcoma is not associated with a higher risk of lymph node metastasis compared with other soft tissue sarcomas. Clin. Orthop. Relat. Res.476 (3), 589598. 10.1007/s11999.0000000000000057

  • 45

    JainA.SaxenaA.MeherR.KhuranaN. (2018). Synovial sarcoma of the ethmoid sinus. Eur. Ann. Otorhinolaryngol. Head. Neck Dis.135 (6), 453455. 10.1016/j.anorl.2017.10.007

  • 46

    JayA.HutchisonI.PiperK.FarthingP. M.RichardsP. S. (2008). Synovial sarcoma presenting as a parotid mass: Case report and review of literature. Head Neck30 (12), 16541659. 10.1002/hed.20822

  • 47

    JayasooriyaP. R.MadawalagamageL. N.MendisB. R.LombardiT. (2016). Diagnostic approach to synovial sarcoma of the head and neck illustrated by two cases arising in the face and oral cavity. Dermatopathol. (Basel)3 (1), 1322. 10.1159/000444876

  • 48

    JernstromP. (1954). Synovial sarcoma of the pharynx; report of a case. Am. J. Clin. Pathol.24 (8), 957961. 10.1093/ajcp/24.8.957

  • 49

    KaoutarC.AhmedouA. B.OukessouY.AbadaR.MohamedR.MohamedM.et al (2021). Aggressive papillary carcinoma of the lateral aberrant thyroide: A case report and review of the LITERATTUREggressive papillary carcinoma of the lateral aberrant thyroide: A case report and review of the literatture. Int. J. Surg. Case Rep.80, 433436. 10.1016/j.ijscr.2020.09.092

  • 50

    KarthaS. S.BumpousJ. M. (2002). Synovial cell sarcoma: Diagnosis, treatment, and outcomes. Laryngoscope112 (11), 19791982. 10.1097/00005537-200211000-00013

  • 51

    KarydakisP.MitsiosA.GiakoumettisD.AntoniadesE.KaragianniA.SfakianosG.et al (2018). Primitive synovial sarcoma of suboccipital region in child. J. Surg. Case Rep.2018 (10), rjy286. 10.1093/jscr/rjy286

  • 52

    KumarS.ShuklaS.AvinashS.FonsecaD.NemadeH.RaoL.et al (2020). Laryngeal synovial sarcoma: A rare clinical entity. Indian J. Surg. Oncol.11 (1), 125127. 10.1007/s13193-020-01097-4

  • 53

    LinN.LiuX.ZhangF.PanY.QiM.ShaY. (2021). Sinonasal synovial sarcoma: Evaluation of the role of radiological and clinicopathological features in diagnosis. Clin. Radiol.76 (1), 78 e1e78.78.e8. 10.1016/j.crad.2020.08.007

  • 54

    LiuK.DuanX.YangL.YuY.LiuB. (2012). Primary synovial sarcoma in the orbit. J. AAPOS16 (6), 582584. 10.1016/j.jaapos.2012.09.002

  • 55

    LiuZ.JinS.FuS.HuY.HeY. (2015). Management of the primary intraosseous synovial sarcoma of the jaws: Be careful of the surgical margin. J. Oral Maxillofac. Surg.73 (3), 550563. 10.1016/j.joms.2014.10.003

  • 56

    LuoC. W.LiuC. J.ChangK. M. (2007). Synovial sarcoma of the temporomandibular joint area: Report of a case. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.104 (4), e62e65. 10.1016/j.tripleo.2007.05.009

  • 57

    MachenS. K.EasleyK. A.GoldblumJ. R. (1999). Synovial sarcoma of the extremities: A clinicopathologic study of 34 cases, including semi-quantitative analysis of spindled, epithelial, and poorly differentiated areas. Am. J. Surg. Pathol.23 (3), 268275. 10.1097/00000478-199903000-00004

  • 58

    MadabhaviI.BhardawaV.ModiM.PatelA.SarkarM. (2018). Primary synovial sarcoma (SS) of larynx: An unusual site. Oral Oncol.79, 8082. 10.1016/j.oraloncology.2018.02.016

  • 59

    MaheshK. T.PonnuswamyI. A.DavidM. P.ShivhareP.PuttaranganayakM. I.SinhaP. (2013). Synovial sarcoma of the buccal mucosa: A rare case report. Case Rep. Dent.2013, 938291. 10.1155/2013/938291

  • 60

    MamelleG.RichardJ.LuboinskiB.SchwaabG.EschwegeF.MicheauC. (1986). Synovial sarcoma of the head and neck: An account of four cases and review of the literature. Eur. J. Surg. Oncol.12 (4), 347349.

  • 61

    MarianoF. V.Oliveira GondakR.da CostaM. V.CorreaM. B.LopesM. A.de AlmeidaO. P. (2012). Primary synovial sarcoma involving the submandibular gland. Oral Surg. Oral Med. Oral Pathol. Oral Radiol.114 (1), e61e65. 10.1016/j.oooo.2011.12.004

  • 62

    MassarelliG.TandaF.SalisB. (1978). Synovial sarcoma of the soft palate: Report of a case. Hum. Pathol.9 (3), 341345. 10.1016/s0046-8177(78)80091-4

  • 63

    MaxymiwW. G.WoodR. E. (1990). Synovial sarcoma of the maxillofacial region with osseous involvement. Case report. Int. J. Oral Maxillofac. Surg.19 (5), 305307. 10.1016/s0901-5027(05)80426-6

  • 64

    MeerS.ColemanH.AltiniM. (2003). Oral synovial sarcoma: A report of 2 cases and a review of the literature. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.96 (3), 306315. 10.1016/s1079-2104(03)00209-9

  • 65

    Mir-AbedyM. (1962). Considerations on the base of the tongue and its tumors. (Apropos of a case of synoviosarcoma and a case of neurofibroma). Ann. Otolaryngol.79, 547561.

  • 66

    MostafapourS. P.FutranN. D. (2000). Tumors and tumorous masses presenting as temporomandibular joint syndrome. Official J. Am. Acad. Otolaryngology-Head Neck Surg.123 (4), 459464. 10.1067/mhn.2000.109662

  • 67

    NaingK. W.MonjazebA. M.LiC-S.LeeL-Y.YangA.BorysD.et al (2015). Perioperative radiotherapy is associated with improved survival among patients with synovial sarcoma: A seer analysis. J. Surg. Oncol.111 (2), 158164. 10.1002/jso.23780

  • 68

    NakahiraM.SugasawaM.MoritaK. (2013). Monophasic synovial sarcoma of the nasopharynx. Auris Nasus Larynx40 (4), 413416. 10.1016/j.anl.2012.07.011

  • 69

    NielsenT. O.PoulinN. M.LadanyiM. (2015). Synovial sarcoma: Recent discoveries as a roadmap to new avenues for therapy. Cancer Discov.5 (2), 124134. 10.1158/2159-8290.CD-14-1246

  • 70

    NomuraF.KishimotoS. (2014). Synovial sarcoma of the temporomandibular joint and infratemporal fossa. Auris Nasus Larynx41 (6), 572575. 10.1016/j.anl.2014.07.001

  • 71

    NovotnyG. M.FortT. C. (1971). Synovial sarcoma of the tongue. Arch. Otolaryngol.94 (1), 7779. 10.1001/archotol.1971.00770070113014

  • 72

    OwoshoA. A.EstiloC. L.RosenE. B.YomS. K.HurynJ. M.AntonescuC. R. (2017). A clinicopathologic study on SS18 fusion positive head and neck synovial sarcomas. Oral Oncol.66, 4651. 10.1016/j.oraloncology.2016.12.021

  • 73

    PaiS.ChinoyR. F.PradhanS. A.D'CruzA. K.KaneS. V.YadavJ. N. (1993). Head and neck synovial sarcomas. J. Surg. Oncol.54 (2), 8286. 10.1002/jso.2930540206

  • 74

    PapaspyrouS.KyriakidesG.TapisM. (2003). Endoscopic CO2 laser surgery for large synovial sarcoma of the larynx. Otolaryngol. Head. Neck Surg.129 (6), 630631. 10.1016/s0194-5998(03)01385-8

  • 75

    PortelliF.PierettiG.SantoroN.GorelliG.De GiorgiV.MassiD.et al (2019). Primary orbital synovial sarcoma mimicking a periocular cyst. Am. J. Dermatopathol.41 (9), 655660. 10.1097/DAD.0000000000001351

  • 76

    PruszczynskiM.ManniJ. J.SmedtsF. (1989). Endolaryngeal synovial sarcoma: Case report with immunohistochemical studies. Head. Neck11 (1), 7680. 10.1002/hed.2880110113

  • 77

    RangheardA. S.VanelD.VialaJ.SchwaabG.CasiraghiO.SigalR. (2001). Synovial sarcomas of the head and neck: CT and MR imaging findings of eight patients. AJNR Am. J. Neuroradiol.22 (5), 851857.

  • 78

    RaoG. V.SravyaT.SivaranjaniY.BhatV. R. (2014). Primary biphasic synovial sarcoma of gingiva: Report of a rare case. J. Oral Maxillofac. Pathol.18 (1), 7780. 10.4103/0973-029X.131916

  • 79

    RatnatungaN.GoodladJ. R.SankarakumaranN.SeimonR.NagendranS.FletcherC. D. (1992). Primary biphasic synovial sarcoma of the orbit. J. Clin. Pathol.45 (3), 265267. 10.1136/jcp.45.3.265

  • 80

    ReillyG.JohnstonG. (2010). Obstructing synovial sarcoma in the trachea of a 10 year old boy. Paediatr. Anaesth.20 (3), 287288. 10.1111/j.1460-9592.2009.03230.x

  • 81

    SaitoS.OzawaH.IkariY.NakaharaN.ItoF.SekimizuM.et al (2018). Synovial sarcoma of the maxillary sinus: An extremely rare case with excellent response to chemotherapy. Onco Targets Ther.11, 483488. 10.2147/OTT.S151473

  • 82

    SantoroA.TurszT.MouridsenH.VerweijJ.StewardW.SomersR.et al (1995). Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group. J. Clin. Oncol.13 (7), 15371545. 10.1200/JCO.1995.13.7.1537

  • 83

    SharmaV.MehanR. (2019). Monophasic synovial sarcoma of tongue: A rarest of rare case scenario. Indian J. Otolaryngol. Head. Neck Surg.71 (1), 585588. 10.1007/s12070-018-1418-0

  • 84

    SheinG.SandhuG.PotterA.LooC.JacobsonI.AnazodoA. (2021). Laryngeal synovial sarcoma: A systematic review of the last 40 Years of reported cases. Ear Nose Throat J.100 (2), NP93NP104. 10.1177/0145561319850697

  • 85

    ShuklaP. N.PathyS.SenS.PurohitA.JulkaP. K.RathG. K. (2003). Primary orbital calcified synovial sarcoma: A case report. Orbit22 (4), 299303. 10.1076/orbi.22.4.299.17246

  • 86

    SingerS.BaldiniE. H.DemetriG. D.FletcherJ. A.CorsonJ. M. (1996). Synovial sarcoma: Prognostic significance of tumor size, margin of resection, and mitotic activity for survival. J. Clin. Oncol.14 (4), 12011208. 10.1200/JCO.1996.14.4.1201

  • 87

    StacchiottiS.Van TineB. A. (2018). Synovial sarcoma: Current concepts and future perspectives. J. Clin. Oncol.36 (2), 180187. 10.1200/JCO.2017.75.1941

  • 88

    StadelmannW. K.CruseC. W.MessinaJ. (1995). Synovial cell sarcoma of the temporomandibular joint. Ann. Plast. Surg.35 (6), 664668. 10.1097/00000637-199512000-00020

  • 89

    StagnerA. M.JakobiecF. A.FayA. (2017). Primary orbital synovial sarcoma: A clinicopathologic review with a differential diagnosis and discussion of molecular genetics. Surv. Ophthalmol.62 (2), 227236. 10.1016/j.survophthal.2016.09.001

  • 90

    SturgisE. M.PotterB. O. (2003). Sarcomas of the head and neck region. Curr. Opin. Oncol.15 (3), 239252. 10.1097/00001622-200305000-00011

  • 91

    SuZ.ZhangJ.GaoP.ShiJ.QiM.ChenL.et al (2018). Synovial sarcoma of the tongue: Report of a case and review of the literature. Ann. R. Coll. Surg. Engl.100 (5), e118e122. 10.1308/rcsann.2018.0045

  • 92

    SubramaniamM. M.ShuenC. S.PeterssonF. (2012). Poorly differentiated synovial sarcoma of the sphenoid sinus: Report of the first case and review of synovial sarcomas of the sinonasal tract. Histopathology61 (6), 12321237. 10.1111/j.1365-2559.2012.04340.x

  • 93

    SultanI.Rodriguez-GalindoC.SaabR.YasirS.CasanovaM.FerrariA. (2009). Comparing children and adults with synovial sarcoma in the surveillance, epidemiology, and end results program, 1983 to 2005: An analysis of 1268 patients. Cancer115 (15), 35373547. 10.1002/cncr.24424

  • 94

    SunJ. J.RasgonB. M.WildT. W.HilsingerR. L.Jr (2003). Synovial cell sarcoma of the maxillary sinus: A first reported case. Otolaryngol. Head. Neck Surg.129 (5), 587590. 10.1016/s0194-5998(03)01392-5

  • 95

    TaoQ.QiaoB.WangY.HuF. (2011). Diagnosis and treatment of primary synovial cell sarcoma that occurred in the left mandible body: A case report and literature review. Oral Surg. Oral Med. Oral Pathology, Oral Radiology, Endod.111 (2), e12e20. 10.1016/j.tripleo.2010.08.025

  • 96

    TateishiU.HasegawaT.BeppuY.SatakeM.MoriyamaN. (2004). Synovial sarcoma of the soft tissues: Prognostic significance of imaging features. J. Comput. Assist. Tomogr.28 (1), 140148. 10.1097/00004728-200401000-00024

  • 97

    TeixeiraL. N.da CruzE. Z.RosaA. C. G.RodriguesA. A.Passador-SantosF.de AraujoV. C.et al (2021). Primary intraosseous synovial sarcoma in the mandible. Case Rep. Oncol. Med.2021, 9945591. 10.1155/2021/9945591

  • 98

    TilakaratneW. M. (2006). Synovial sarcoma of the mandible. J. Oral Pathol. Med.35 (1), 6163. 10.1111/j.1600-0714.2005.00375.x

  • 99

    TrassardM.Le DoussalV.HaceneK.TerrierP.RanchereD.GuillouL.et al (2001). Prognostic factors in localized primary synovial sarcoma: A multicenter study of 128 adult patients. J. Clin. Oncol.19 (2), 525534. 10.1200/JCO.2001.19.2.525

  • 100

    TribleW. M. (1970). Destructive lesions of the sphenoid. South Med. J.63 (7), 849852. 10.1097/00007611-197007000-00023

  • 101

    UlusanS.KizilkilicO.YildirimT.HurcanC.BalN.NursalT. Z. (2005). Radiological findings of primary retroperitoneal synovial sarcoma. Br. J. Radiol.78 (926), 166169. 10.1259/bjr/67990800

  • 102

    VenkatramaniR.XueW.RandallR. L.WoldenS.AndersonJ.Lopez-TerradaD.et al (2021). Synovial sarcoma in children, adolescents, and young adults: A report from the children's Oncology group ARST0332 study. J. Clin. Oncol.39 (35), 39273937. 10.1200/JCO.21.01628

  • 103

    Villaroel-SalinasJ.Campos-MartinezJ.Ortiz-HidalgoC. (2012). Synovial sarcoma of the tongue confirmed by molecular detection of the SYT-SSX2 fusion gene transcript. Int. J. Surg. Pathol.20 (4), 386389. 10.1177/1066896911424897

  • 104

    ViningC. C.SinnamonA. J.EckerB. L.KelzR. R.FrakerD. L.RosesR. E.et al (2017). Adjuvant chemotherapy in resectable synovial sarcoma. J. Surg. Oncol.116 (4), 550558. 10.1002/jso.24688

  • 105

    VotrubaM.HungerfordJ.CornesP. G. S.MabeyD.LuthertP. (2002). Primary monophasic synovial sarcoma of the conjunctiva. Br. J. Ophthalmol.86 (12), 14531454. 10.1136/bjo.86.12.1453

  • 106

    WangH.ZhangJ.HeX.NiuY. (2008). Synovial sarcoma in the oral and maxillofacial region: Report of 4 cases and review of the literature. J. Oral Maxillofac. Surg.66 (1), 161167. 10.1016/j.joms.2007.05.007

  • 107

    WangY.ZhuF.WangK. (2020). Synovial sarcoma of the floor of the mouth: A rare case report. BMC Oral Health20 (1), 5. 10.1186/s12903-019-0961-8

  • 108

    WhiteR. D.MakarJ.Jr.StecklerR. M. (1992). Synovial sarcoma of the temporomandibular joint. J. Oral Maxillofac. Surg.50 (11), 12271230. 10.1016/0278-2391(92)90160-2

  • 109

    WigandM. C.HoffmannT. K.BarthT. F. E.VeitJ. (2018). Biphasic synovial sarcoma of the epiglottis: Case report and literature review. Auris Nasus Larynx45 (3), 617621. 10.1016/j.anl.2017.06.007

  • 110

    WongH. T.HoC. Y.NazarinaA. R.PrepageranN. (2014). Synovial sarcoma of the ethmoidal sinus. J. Laryngol. Otol.128 (11), 10221023. 10.1017/S0022215114002151

  • 111

    WushouA.MiaoX. C. (2015). Tumor size predicts prognosis of head and neck synovial cell sarcoma. Oncol. Lett.9 (1), 381386. 10.3892/ol.2014.2634

  • 112

    XiaS.ChenX.HuY.ZhangJ. (2020). Biphasic synovial sarcoma with extensive calcification in the temporomandibular joint region: A rare case report and literature review. J. Stomatol. Oral Maxillofac. Surg.121 (5), 592598. 10.1016/j.jormas.2020.02.005

  • 113

    XuP.ChenJ. (2017). Primary synovial sarcoma of the orbit. Ophthalmol. Eye Dis.9, 1179172117701732. 10.1177/1179172117701732

Summary

Keywords

synovial sarcoma of the head and neck, diagnosis, treatments, clinical manifestations, management

Citation

Quan H, Sreekissoon S and Wang Y (2023) Synovial sarcoma of the head and neck: A review of reported cases on the clinical characteristics and treatment methods. Front. Cell Dev. Biol. 10:1077756. doi: 10.3389/fcell.2022.1077756

Received

23 October 2022

Accepted

12 December 2022

Published

06 January 2023

Volume

10 - 2022

Edited by

Wei Han, Nanjing University, China

Reviewed by

Xin Peng, Peking University Hospital of Stomatology, China

Shanghui Zhou, Shanghai Jiao Tong University, China

Updates

Copyright

*Correspondence: Hongzhi Quan,

This article was submitted to Cancer Cell Biology, a section of the journal Frontiers in Cell and Developmental Biology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics